8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Whole Body / General

Jin H, Kim K, Park GY, Kim M, Lee H-J, Jeon S, Kim JH, Kim HR, Lim KM, Lee YS

Bioeffects Seen

Authors not listed · 2021

Share:

Chronic kidney disease patients face increased infection and cancer risks that EMF research has largely ignored.

Plain English Summary

Summary written for general audiences

This study examined dapagliflozin, a diabetes medication, in patients with chronic kidney disease over 2.4 years. Researchers found the drug reduced death rates by 31%, primarily by preventing deaths from infections and cancer rather than heart problems. The findings suggest this medication helps kidney disease patients live longer.

Why This Matters

While this pharmaceutical study appears unrelated to EMF research at first glance, it actually highlights a critical gap in our understanding of how electromagnetic field exposure affects vulnerable populations like those with chronic kidney disease. The study's finding that infections and malignancies were leading causes of death in CKD patients is particularly relevant, given emerging research suggesting EMF exposure may compromise immune function and potentially influence cancer development. What's concerning is that patients with kidney disease may be especially susceptible to EMF effects due to their already compromised physiological state, yet no major clinical trials examining EMF impacts include these vulnerable populations. The reality is that people with chronic conditions like CKD are using the same wireless devices and living in the same EMF-saturated environments as healthy individuals, but we have virtually no data on whether their health risks are amplified.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2021). Jin H, Kim K, Park GY, Kim M, Lee H-J, Jeon S, Kim JH, Kim HR, Lim KM, Lee YS.
Show BibTeX
@article{jin_h_kim_k_park_gy_kim_m_lee_h_j_jeon_s_kim_jh_kim_hr_lim_km_lee_ys_ce2840,
  author = {Unknown},
  title = {Jin H, Kim K, Park GY, Kim M, Lee H-J, Jeon S, Kim JH, Kim HR, Lim KM, Lee YS},
  year = {2021},
  doi = {10.1093/eurheartj/ehab094},
  
}
DOI: 10.1093/eurheartj/ehab094PubMed: 33792669

Quick Questions About This Study

Yes, the DAPA-CKD trial found dapagliflozin reduced all-cause mortality by 31% in chronic kidney disease patients over 2.4 years of treatment, with particularly strong effects on preventing non-cardiovascular deaths.
In this study, 41.3% of deaths were from non-cardiovascular causes (primarily infections and malignancies), 36.8% from cardiovascular causes, and 21.9% had undetermined causes among the 247 patients who died.
The DAPA-CKD trial included 4,304 participants with chronic kidney disease, randomly assigned to receive either dapagliflozin 10 mg daily (2,152 patients) or placebo (2,152 patients) for median follow-up of 2.4 years.
Eligible patients had estimated glomerular filtration rate (eGFR) between 25-75 mL/min/1.73 m² and urinary albumin-to-creatinine ratio (UACR) of 200-5000 mg/g, indicating moderate to severe chronic kidney disease with protein in urine.
Yes, the 31% reduction in all-cause mortality with dapagliflozin was consistent across all pre-specified subgroups analyzed in the study, suggesting the survival benefit applies broadly to chronic kidney disease patients.